Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Hepatology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0168-8278(00)00074-XPMID 11211887
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B

  2000cited by this paper
• Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.

  2000cited by this paper
• Line Probe Assay for Monitoring Drug Resistance in Hepatitis B Virus-Infected Patients during Antiviral Therapy

  2000cited by this paper
• Characterization of the Antiviral Effect of 2′,3′-Dideoxy-2′, 3′-Didehydro-β-l-5-Fluorocytidine in the Duck Hepatitis B Virus Infection Model

  2000cited by this paper
• Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance

  1999cited by this paper
• Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues.

  1999cited by this paper
• Lamivudine as initial treatment for chronic hepatitis B in the United States.

  1999cited by this paper
• Residues Critical for Duck Hepatitis B Virus Neutralization Are Involved in Host Cell Interaction

  1999cited by this paper
• Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.

  1999cited by this paper
• YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitrofull‐length viral DNA transfection

  1999cited by this paper
• Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy

  1999cited by this paper
• Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

  1999cited by this paper
• Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

  1999cited by this paper
• Emergence of Drug-Resistant Populations of Woodchuck Hepatitis Virus in Woodchucks Treated with the Antiviral Nucleoside Lamivudine

  1999cited by this paper
• Inhibitory Effect of 2′-Fluoro-5-Methyl-β-l-Arabinofuranosyl-Uracil on Duck Hepatitis B Virus Replication

  1998cited by this paper
• Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.

  1998cited by this paper
• Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

  1998cited by this paper
• Lamivudine therapy of WHV-infected woodchucks.

  1998cited by this paper
• The M539V Polymerase Variant of Human Hepatitis B Virus Demonstrates Resistance to 2′-Deoxy-3′-Thiacytidine and a Reduced Ability to Synthesize Viral DNA

  1998cited by this paper
• Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

  1998cited by this paper
• The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.

  1998cited by this paper
• Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance.

  1998cited by this paper
• Emergence and takeover of YMDD motif mutant hepatitis B virus during long‐term lamivudine therapy and re‐takeover by wild type after cessation of therapy

  1998cited by this paper
• Identification and characterization of mutations in hepatitis B virus resistant to lamivudine

  1998cited by this paper
• Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.

  1998cited by this paper
• A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

  1998cited by this paper
• The treatment of chronic viral hepatitis.

  1997cited by this paper
• Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus

  1997cited by this paper
• Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase

  1997cited by this paper
• Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation.

  1997cited by this paper
• Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns.

  1997cited by this paper
• Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study.

  1997cited by this paper
• Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles

  1997cited by this paper
• Lamivudine resistance inimmunocompetent chronic hepatitis B

  1997cited by this paper
• THE TREATMENT OF CHRONIC VIRAL HEPATITIS

  1997cited by this paper
• Inhibitory Effect of Penciclovir-Triphosphate on Duck Hepatitis B Virus Reverse Transcription

  1997cited by this paper
• 2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo

  1996cited by this paper
• Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(--)-beta-L-2', 3'-dideoxy-3'-thiacytidine] in vitro

  1996cited by this paper
• Mutation in HBV RNA‐dependent DNA polymerase confers resistance to lamivudine in vivo

  1996cited by this paper
• Reduced replication of 3TC‐resistant HIV‐1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

  1996cited by this paper
• Viral dynamics in hepatitis B virus infection.

  1996cited by this paper
• Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

  1996cited by this paper
• Use of novel beta-L(-)-nucleoside analogues for treatment and prevention of chronic hepatitis B virus infection and hepatocellular carcinoma.

  1995cited by this paper
• Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells

  1995cited by this paper
• Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine

  1995cited by this paper
• Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro

  1995cited by this paper
• Hepatitis B reactivation after lamivudine.

  1995cited by this paper
• Woodchuck hepatitis virus X protein is required for viral infection in vivo

  1994cited by this paper
• Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase

  1994cited by this paper
• The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis.

  1992cited by this paper
• Replication of DHBV genomes with mutations at the sites of initiation of minus- and plus-strand DNA synthesis.

  1992cited by this paper
• Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues.

  1991cited by this paper
• Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification

  1990cited by this paper
• Synthesis of hepadnavirus particles that contain replication-defective duck hepatitis B virus genomes in cultured HuH7 cells

  1990cited by this paper
• Duck hepatitis B virus can tolerate insertion, deletion, and partial frameshift mutation in the distal pre-S region

  1989cited by this paper
• Homologous recombination between hepadnaviral genomes following in vivo DNA transfection: implications for studies of viral infectivity.

  1987cited by this paper
• Nucleotide sequence of a cloned duck hepatitis B virus genome: comparison with woodchuck and human hepatitis B virus sequences

  1984cited by this paper
• Cloned duck hepatitis B virus DNA is infectious in Pekin ducks

  1984cited by this paper
• Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate.

  1982cited by this paper
• Progress in Liver Diseases

  1962cited by this paper

• Molecular characterization of occult hepatitis B virus infection in patients with end-stage liver disease in Colombia

  2017cites this paper
• Sequential analysis of amino acid substitutions with hepatitis B virus in association with nucleoside/nucleotide analog treatment detected by deep sequencing

  2014cites this paper
• Comprehensive analysis of Hepatitis B virus antiviral drug resistance mutations based on a new high-throughput phenotypic assay

  2013cites this paper
• Human Diseases Prosecution Among Viral Infection and Food Toxins: A Review

  2013cites this paper
• Management of treatment failure in chronic hepatitis B.

  2012cites this paper
• Humanized murine model for HBV and HCV using human induced pluripotent stem cells

  2012cites this paper
• Humanized murine model for HBV and HCV using human induced pluripotent stem cells

  2012cites this paper
• The role of the programmed cell death (PD-1) pathway in the immunopathogenesis of chronic hepatitis B infection

  2011cites this paper
• HEP-05-0036.R1 Susceptibility to Antivirals of an HBV Strain With Mutations Conferring Resistance to Both Lamivudine and Adefovir

  2009cites this paper
• Systematic review: combination therapies for treatment‐naïve chronic hepatitis B

  2008cites this paper
• Hepatitis B: reflections on the current approach to antiviral therapy.

  2008cites this paper
• Reverse transcriptase activity of hepatitis B virus polymerase in eukaryotic cell extracts in vitro.

  2008influential citation
• Pharmacokinetics, safety and tolerance of single- and multiple-dose adefovir dipivoxil in healthy Chinese subjects.

  2007cites this paper
• Protocatechuic aldehyde inhibits hepatitis B virus replication both in vitro and in vivo.

  2007cites this paper
• Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.

  2007cites this paper
• In Vitro Models for Studying Hepatitis B Virus Drug Resistance

  2006cites this paper
• Antiviral therapy targeting viral polymerase.

  2006cites this paper
• In vitro models for studying hepatitis B virus drug resistance.

  2006cites this paper
• In Vitro Characterization of the Anti-Hepatitis B Virus Activity and Cross-Resistance Profile of 2′,3′-Dideoxy-3′-Fluoroguanosine

  2006cites this paper
• A novel accurate ACRS-PCR method with a digestion internal control for identification of wild type and YMDD mutants of hepatitis B virus strains.

  2006cites this paper
• Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir

  2005cites this paper
• Activity of adefovir dipivoxil against all patterns of lamivudine‐resistant hepatitis B viruses in patients

  2005cites this paper
• Mutations outside the YMDD motif in the P protein can also cause DHBV resistant to Lamivudine.

  2005cites this paper
• Study of HBV replication capacity in relation to sequence variation in the precore and core promoter regions.

  2004cites this paper
• Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection.

  2004cites this paper
• Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy

  2004cites this paper
• Combinations of Adefovir with Nucleoside Analogs Produce Additive Antiviral Effects against Hepatitis B Virus In Vitro

  2004cites this paper
• Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

  2003cites this paper
• Hepatitis B virus resistance to antivirals: clinical implications and management.

  2003cites this paper
• Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model.

  2003cites this paper
• Effects of Pyrimidine and Purine Analog Combinations in the Duck Hepatitis B Virus Infection Model

  2003cites this paper
• Assessing Hepatitis B Virus Resistance In Vitro and Molecular Mechanisms of Nucleoside Resistance

  2002cites this paper
• Inhibitory activity of dioxolane purine analogs on wild‐type and lamivudine‐resistant mutants of hepadnaviruses

  2002cites this paper
• Inhibitory Effect of Adefovir on Viral DNA Synthesis and Covalently Closed Circular DNA Formation in Duck Hepatitis B Virus-Infected Hepatocytes In Vivo and In Vitro

  2002cites this paper
• Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine.

  2002cites this paper
• Hépatite chronique virale B : actualités thérapeutiques

  2001cites this paper
• Quantification and genotyping in management of chronic hepatitis B and C.

  2001cites this paper
• [Current knowledge on chronic hepatitis B therapy].

  2001cites this paper
• Nouveaux traitements de l'hépatite B et techniques d'étude de la résistance virale

  2001cites this paper
• Is lamivudine effective on precore/core promoter mutants of hepatitis B virus?

  2000cites this paper
• Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B

  2000cites this paper